"Prostaglandin D2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.
| Descriptor ID |
D015230
|
| MeSH Number(s) |
D10.251.355.255.550.200.200 D23.469.050.175.725.200.200
|
| Concept/Terms |
Prostaglandin D2- Prostaglandin D2
- D2, Prostaglandin
- 11-Dehydroprostaglandin F2 alpha
- 11 Dehydroprostaglandin F2 alpha
- F2 alpha, 11-Dehydroprostaglandin
- alpha, 11-Dehydroprostaglandin F2
- PGD2
- 11-Dehydroprostaglandin F2alpha
- 11 Dehydroprostaglandin F2alpha
- F2alpha, 11-Dehydroprostaglandin
|
Below are MeSH descriptors whose meaning is more general than "Prostaglandin D2".
Below are MeSH descriptors whose meaning is more specific than "Prostaglandin D2".
This graph shows the total number of publications written about "Prostaglandin D2" by people in this website by year, and whether "Prostaglandin D2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostaglandin D2" by people in Profiles.
-
Characterization of Mast Cell Activation Syndrome. Am J Med Sci. 2017 03; 353(3):207-215.
-
Mast cells contribute to altered vascular reactivity and ischemia-reperfusion injury following cerium oxide nanoparticle instillation. Nanotoxicology. 2011 Dec; 5(4):531-45.
-
A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. Int Immunol. 2009 Jan; 21(1):81-93.
-
Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms. Int Immunol. 2009 Jan; 21(1):1-17.
-
The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood. 2007 Feb 01; 109(3):1077-85.
-
The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. J Immunol. 2004 Oct 15; 173(8):5196-208.
-
Peroxisome proliferator-activated receptor-gamma agonists modulate macrophage activation by gram-negative and gram-positive bacterial stimuli. Shock. 2003 Jul; 20(1):56-62.
-
Upregulation of interleukin-8 expression by prostaglandin D2 metabolite 15-deoxy-delta12, 14 prostaglandin J2 (15d-PGJ2) in human THP-1 macrophages. Atherosclerosis. 2002 Jan; 160(1):11-20.
-
Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation. J Leukoc Biol. 2001 Apr; 69(4):631-8.
-
Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin Immunol. 2001 Mar; 98(3):337-45.